Evidence map›Paper›PMID 40848614›Full record

ArticleNeoplasia (New York, N.Y.)2025

Neuropilin-2 upregulation by stromal TGFβ1 induces lung disseminated tumor cells dormancy escape and promotes metastasis outgrowth.

L Recalde-Percaz, I de la Guia-Lopez, P Linzoain-Agos, A Noguera-Castells, M Rodrigo-Faus, P Jauregui, A Lopez-Plana, P Fernández-Nogueira, M Iniesta-González, M Cueto-Remacha and 18 more

Abstract read
In one paragraph

Article in Neoplasia (New York, N.Y.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

L Recalde-PercazDepartment of Biomedicine, School of Medicine, Universitat de Barcelona, 08036 Barcelona, Spain; Department of Biochemistry and Molecular Biomedicine, Faculty of Biology, Institute of Biomedicine (IBUB), Universitat de Barcelona, 08028 Barcelona, Spain.
I de la Guia-LopezDepartment of Biochemistry and Molecular Biology, Faculty of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain; Health Research Institute of the Hospital Clínico San Carlos, 28040 Madrid, Spain.
P Linzoain-AgosDepartment of Biochemistry and Molecular Biology, Faculty of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain; Health Research Institute of the Hospital Clínico San Carlos, 28040 Madrid, Spain.
A Noguera-CastellsDepartment of Biomedicine, School of Medicine, Universitat de Barcelona, 08036 Barcelona, Spain; Department of Biochemistry and Molecular Biomedicine, Faculty of Biology, Institute of Biomedicine (IBUB), Universitat de Barcelona, 08028 Barcelona, Spain.
M Rodrigo-FausDepartment of Biochemistry and Molecular Biology, Faculty of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain; Health Research Institute of the Hospital Clínico San Carlos, 28040 Madrid, Spain.
P JaureguiDepartment of Biomedicine, School of Medicine, Universitat de Barcelona, 08036 Barcelona, Spain.
A Lopez-PlanaDepartment of Biomedicine, School of Medicine, Universitat de Barcelona, 08036 Barcelona, Spain; Department of Biochemistry and Molecular Biomedicine, Faculty of Biology, Institute of Biomedicine (IBUB), Universitat de Barcelona, 08028 Barcelona, Spain.
P Fernández-NogueiraDepartment of Biomedicine, School of Medicine, Universitat de Barcelona, 08036 Barcelona, Spain; Department of Biochemistry and Molecular Biomedicine, Faculty of Biology, Institute of Biomedicine (IBUB), Universitat de Barcelona, 08028 Barcelona, Spain; Unit of Biophysics and Bioengineering, Department of Biomedicine, School of Medicine and Health Sciences, Universitat de Barcelona, Barcelona, Spain.
M Iniesta-GonzálezDepartment of Biochemistry and Molecular Biology, Faculty of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain; Health Research Institute of the Hospital Clínico San Carlos, 28040 Madrid, Spain.
M Cueto-RemachaDepartment of Biochemistry and Molecular Biology, Faculty of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain; Health Research Institute of the Hospital Clínico San Carlos, 28040 Madrid, Spain.
S ManzanoDepartment of Biochemistry and Molecular Biology, Faculty of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain; Health Research Institute of the Hospital Clínico San Carlos, 28040 Madrid, Spain; Instituto de Investigación Sanitaria (IIS) Biodonostia, 20014 San Sebastián/Donosti, Spain.
R AlonsoDepartment of Biomedicine, School of Medicine, Universitat de Barcelona, 08036 Barcelona, Spain.
N MoragasDepartment of Biomedicine, School of Medicine, Universitat de Barcelona, 08036 Barcelona, Spain; Department of Biochemistry and Molecular Biomedicine, Faculty of Biology, Institute of Biomedicine (IBUB), Universitat de Barcelona, 08028 Barcelona, Spain.
C BaqueroDepartment of Biochemistry and Molecular Biology, Faculty of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain; Health Research Institute of the Hospital Clínico San Carlos, 28040 Madrid, Spain.
N PalaoDepartment of Biochemistry and Molecular Biology, Faculty of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain; Health Research Institute of the Hospital Clínico San Carlos, 28040 Madrid, Spain.
E DallaDepartment of Cell Biology, Cancer Dormancy and Tumor Microenvironment Institute, Albert Einstein Cancer Center, Albert Einstein College of Medicine, New York, NY, USA.
F X Avilés-JuradoFunctional Unit of Head and Neck Tumors. Otorhinolaryngology Head-Neck Surgery Department, Hospital Clínic, Barcelona, Spain; Translational Genomics and Target Therapies in Solid Tumors Group. Institut d´Investigacions Biomèdiques August Pi i Sunyer. IDIBAPS, Barcelona, Spain; Surgery and Medical-Surgical Specialties Department. Faculty of Medicine and Health Sciences. Universitat de Barcelona. Barcelona, Spain.
I VilasecaFunctional Unit of Head and Neck Tumors. Otorhinolaryngology Head-Neck Surgery Department, Hospital Clínic, Barcelona, Spain; Translational Genomics and Target Therapies in Solid Tumors Group. Institut d´Investigacions Biomèdiques August Pi i Sunyer. IDIBAPS, Barcelona, Spain; Surgery and Medical-Surgical Specialties Department. Faculty of Medicine and Health Sciences. Universitat de Barcelona. Barcelona, Spain.
X León-VintróOtorhinolaryngology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, 08193 Barcelona, Spain; Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), 28001 Madrid, Spain.
M CamachoGenomics of Complex Diseases, Research Institute Hospital Sant Pau, IIB Sant Pau, 08041 Barcelona, Spain.
G FusterDepartment of Biomedicine, School of Medicine, Universitat de Barcelona, 08036 Barcelona, Spain; Department of Biochemistry and Molecular Biomedicine, Faculty of Biology, Institute of Biomedicine (IBUB), Universitat de Barcelona, 08028 Barcelona, Spain; Department of Biosciences, Faculty of Sciences and Technology, University of Vic, 08500 Vic, Spain.
J AlcarazUnit of Biophysics and Bioengineering, Department of Biomedicine, School of Medicine and Health Sciences, Universitat de Barcelona, Barcelona, Spain; Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute for Science and Technology (BIST), Barcelona 08028, Spain.
J Aguirre-GhisoDepartment of Cell Biology, Cancer Dormancy and Tumor Microenvironment Institute, Albert Einstein Cancer Center, Albert Einstein College of Medicine, New York, NY, USA; Gruss-Lipper Biophotonics Center, Ruth L. and David S. Gottesman Institute for Stem Cell Research and Regenerative Medicine Albert Einstein Cancer Center, Albert Einstein College of Medicine, New York, NY, USA.
P GascónDepartment of Biomedicine, School of Medicine, Universitat de Barcelona, 08036 Barcelona, Spain; Department of Biochemistry and Molecular Biomedicine, Faculty of Biology, Institute of Biomedicine (IBUB), Universitat de Barcelona, 08028 Barcelona, Spain.
A PorrasDepartment of Biochemistry and Molecular Biology, Faculty of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain; Health Research Institute of the Hospital Clínico San Carlos, 28040 Madrid, Spain.
A Gutiérrez-UzquizaDepartment of Biochemistry and Molecular Biology, Faculty of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain; Health Research Institute of the Hospital Clínico San Carlos, 28040 Madrid, Spain.
N CarbóDepartment of Biochemistry and Molecular Biomedicine, Faculty of Biology, Institute of Biomedicine (IBUB), Universitat de Barcelona, 08028 Barcelona, Spain.
P BragadoDepartment of Biochemistry and Molecular Biology, Faculty of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain; Health Research Institute of the Hospital Clínico San Carlos, 28040 Madrid, Spain. Electronic address: pbragado@ucm.es.

Funding

Functional Determinants of Metastatic DormancyR01CA109182 · NCI · STATE UNIVERSITY OF NEW YORK AT ALBANY · PI AGUIRRE-GHISO, JULIO A. · 2005 to 2025
$8.3M
Madrid Community Program for Talent AttractionNCI NIH HHS R01 CA109182
6 · The paper itself

Abstract

Metastasis is the main cause of death from solid tumors. Therefore, identifying the mechanisms that govern metastatic growth poses a major biomedical challenge. Tumor microenvironment signals regulate the fate and survival of disseminated tumor cells (DTCs) in secondary organs. However, very little is known about the role of nervous system mediators in this process. We have previously reported that neuropilin-2 (NRP2) expression in breast cancer correlates with poor prognosis. Here, we show that NRP2 positively regulates the proliferation, invasion, and survival of breast and head and neck cancer cells in vitro. NRP2 deletion in tumor cells inhibits tumor growth in vivo and decreases the number and size of lung metastases by promoting lung DTCs quiescence. NRP2 deletion upregulates dormancy and cell cycle regulators expression and promotes DTCs reprograming into quiescence. Moreover, lung fibroblasts and macrophages induce NRP2 upregulation in DTCs through the secretion of TGFβ1. NRP2 facilitates lung DTC interaction with the extracellular matrix and promotes lung DTCs activation and metastasis. Therefore, we conclude that the TGFβ1-NRP2 axis is a new key dormancy-awakening inducer that promotes DTCs proliferation and lung metastasis development.

Indexed as

Lung NeoplasmsNeuropilin-2Transforming Growth Factor beta1AnimalsCell Line, TumorCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansMiceNeoplasm MetastasisStromal CellsTumor MicroenvironmentUp-RegulationNeuropilin-2neuropilin-2, humanTGFB1 protein, humanTransforming Growth Factor beta1breast cancerdisseminated tumor cellsdormancyhead and neck cancermetastasisNeuropilinsTGFβ

Identifiers

PMID40848614
PMCPMC12446975

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.